Welcome to our dedicated page for Veradermics SEC filings (Ticker: MANE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Veradermics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Veradermics's regulatory disclosures and financial reporting.
Veradermics, Incorporated filed a resale registration covering up to 16,772,058 shares of common stock and up to 300,000 shares issuable upon exercise of pre-funded warrants. All registered shares may be sold from time to time by existing selling stockholders; Veradermics is not selling shares and will not receive proceeds from these resales, other than potential cash from warrant exercises at an exercise price of $0.00001 per share.
The Resale Shares represent approximately 40.6% of the 41,780,136 shares of common stock outstanding as of June 30, 2026, which could materially expand tradable float. Veradermics is a dermatologist‑founded, late clinical‑stage biopharmaceutical company focused on pattern hair loss, led by oral extended‑release minoxidil candidate VDPHL01, and qualifies as an emerging growth and smaller reporting company using reduced disclosure.
FMR LLC and associated person Abigail P. Johnson report a significant passive ownership position in Veradermics Inc. common stock. They disclose beneficial ownership of 3,193,181 shares of common stock, representing 7.6 % of the outstanding class as of June 30, 2026.
FMR LLC reports sole voting power over 3,193,077 shares and sole dispositive power over 3,193,181 shares, with no shared voting or dispositive power. Abigail P. Johnson is reported as having sole dispositive power over 3,193,181 shares and no voting power, reflecting her control position through FMR LLC and its subsidiaries.
The filing notes that one or more other persons have the right to receive dividends or sale proceeds related to these shares, but no such person holds an interest exceeding 5 % of Veradermics Inc. common stock. The securities are held through subsidiaries identified in an accompanying Exhibit 99.
Veradermics, Incorporated reported positive topline Phase 2 data from Study ‘207’ of VDPHL01, an extended-release oral minoxidil tablet, in women with mild-to-moderate pattern hair loss. Female participants receiving 4.5 mg once or twice daily for 6 months showed objective hair growth and high patient-reported benefit.
Average non-vellus Target Area Hair Count increased 22.7 hairs/cm² in the once-daily arm and 23.3 hairs/cm² in the twice-daily arm at Month 6. On the Androgenetic Alopecia Impact Rating Scale, 88.9% (once-daily) and 90.0% (twice-daily) of women reported ‘improved’ or ‘much improved’ hair coverage, while investigators graded 100% and 90% of participants, respectively, as improved. Improvement was already seen at Month 2, with investigators and patients reporting benefits in 67.2% and 63.2% of participants.
VDPHL01 was generally well tolerated through Month 6, with no treatment-related serious adverse events and no cardiac adverse events of special interest; the most common adverse events were hypertrichosis and peripheral edema. Veradermics is running registration-directed Phase 2/3 trials in male and female pattern hair loss, with key topline readouts expected in 2026–2027.
Veradermics, Inc ownership disclosure: Viking Global Investors and affiliated entities report shared beneficial ownership of 1,690,555 shares of Common Stock. The filing states these holdings represent 4.5% of the class based on 37,340,290 shares outstanding as of March 31, 2026.
The schedule details the allocation across affiliated vehicles: VGOP and related GP entities beneficially own 1,014,331 shares (2.7%), while VGOD and related GP entities beneficially own 676,224 shares (1.8%). The amendment also removes David C. Ott as a reporting person effective March 31, 2026.
Veradermics, Incorporated reported a net loss of $27.2 million for the three months ended March 31, 2026, as it increased investment in late-stage dermatology programs. Research and development expenses rose to $20.9 million and general and administrative costs reached $8.9 million, reflecting expanded clinical activity and public-company readiness.
The company strengthened its balance sheet with an IPO in February 2026 generating net proceeds of $269.1 million, bringing cash, cash equivalents and marketable securities to $390.8 million as of March 31, 2026. Subsequent May 2026 follow-on and private offerings added $472.0 million in gross proceeds to support development of lead candidate VDPHL01 and its broader dermatology pipeline.
Veradermics, Inc. reported a larger net loss for the first quarter of 2026 as it accelerated late-stage development of its lead hair-loss drug VDPHL01 and strengthened its balance sheet. Net loss was $27.2 million, compared with $12.4 million a year earlier, driven by higher R&D and G&A spending.
Cash, cash equivalents and marketable securities were $390.8 million as of March 31, 2026, reflecting proceeds from an upsized IPO in February. A follow-on offering completed after quarter-end raised an additional $472.0 million in gross proceeds, contributing to an aggregate $766.8 million raised in 2026 and a projected cash runway into 2030.
The company highlighted positive topline results from Part A of Phase 2/3 Study ‘302’ of oral, extended-release minoxidil tablet VDPHL01 in male pattern hair loss, completion of enrollment in confirmatory Phase 3 Study ‘304’, and ongoing enrollment in Phase 2/3 Study ‘306’ in women, positioning VDPHL01 as a potential first-in-class non-hormonal oral treatment.
Veradermics, Incorporated ownership disclosure: Citadel Advisors LLC and related reporting persons report shared beneficial ownership of 1,870,775 shares of Common Stock. The filing states this position represents 4.5% of shares outstanding based on 41,183,254 Shares outstanding as of May 1, 2026.
The joint filing lists the reporting group (Citadel Advisors, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities entities and Kenneth Griffin) and details shared voting and dispositive power over the reported shares. Signature blocks show the statement was filed on behalf of the reporting persons.
Suvretta Capital–related funds filed Amendment No. 1 to their Schedule 13D on Veradermics, Inc., updating their ownership and warrant holdings. Suvretta Capital Management and Aaron Cowen report beneficial ownership of 4,172,121 shares of common stock, representing 9.9% of the class, including 3,151 shares issuable upon exercise of Pre-Funded Warrants.
Averill Master Fund, Ltd. reports 3,650,103 shares, or 8.7% of the class, and Averill Madison Master Fund, Ltd. reports 522,018 shares, or 1.2%. The amendment describes an April 29, 2026 Securities Purchase Agreement under which Averill Master Fund acquired 149,000 Pre-Funded Warrants and Averill Madison Master Fund acquired 151,000, each at $99.99999 per warrant with a $0.00001 exercise price, subject to a Beneficial Ownership Limitation of generally 9.99%, or up to 19.99% upon election.
Veradermics, Inc. investment entities reported new derivative awards rather than open-market trades. On May 1, 2026, reporting persons including Suvretta Capital Management, LLC and Averill funds reported the indirect acquisition of two blocks of Pre-Funded Warrants for 151,000 and 149,000 underlying shares of Veradermics common stock. These transactions are coded as grants or awards, so they increase indirect exposure to Veradermics without reflecting discretionary buying or selling in the open market.
Veradermics, Incorporated received an updated ownership filing from Longitude-affiliated investment funds and their managers. The group reports beneficial ownership of Veradermics common stock through several Delaware entities and two individual managers, reflecting coordinated investment positions.
Longitude Venture Partners V, L.P. and related entities report 2,600,399 shares, or 6.3% of the common stock, while Longitude 103.8 East, L.P. and its affiliates report 2,053,474 shares, or 5.0%. Individually, Patrick G. Enright and Juliet Tammenoms Bakker are each deemed to beneficially own 4,653,873 shares, representing 11.3% of Veradermics’ 41,184,080 shares outstanding. The filing details shared voting and dispositive power across these funds and clarifies that each reporting person generally disclaims beneficial ownership beyond their pecuniary interest.